Investments envisage the development of two new production lines for beta-lactamic and injectable antibiotics. Moreover, the Romanian company is also developing a new research center in a bid to launch new products.
In parallel, the company continues to invest in sustainability and green transition.
Antibiotice Iasi for H1/2024 reported RON74 million net profit, up 20% from the year earlier period, while revenues climbed by 8% to RON380 million.
The company has a RON2 billion capitalization. Since the start of 2024, its shares have added 129%.
(English version by Catalina Apostoiu)